BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 30597022)

  • 21. Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma.
    Parikh RR; Grossbard ML; Harrison LB; Yahalom J
    Radiother Oncol; 2016 Jan; 118(1):52-9. PubMed ID: 26522061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of surgery plus postoperative radiotherapy or definitive radiotherapy in older patients with thoracic esophageal squamous cell cancer.
    Jiang W; Sun X; Zhou B; Han C; Liu F; Zheng J; Sun X
    J Cancer Res Ther; 2019; 15(4):849-856. PubMed ID: 31436242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients.
    Lester SC; Lin SH; Chuong M; Bhooshan N; Liao Z; Arnett AL; James SE; Evans JD; Spears GM; Komaki R; Haddock MG; Mehta MP; Hallemeier CL; Merrell KW
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):820-828. PubMed ID: 28476435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
    Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
    Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting.
    Murphy CC; Hofstetter WL; Correa AM; Ajani JA; Komaki RU; Swisher SG
    Dis Esophagus; 2013; 26(7):708-15. PubMed ID: 23350713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
    Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
    JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating Intensity-Modulated Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer: Results From the National CancerĀ Data Base.
    Jegadeesh N; Liu Y; Gillespie T; Fernandez F; Ramalingam S; Mikell J; Lipscomb J; Curran WJ; Higgins KA
    Clin Lung Cancer; 2016 Sep; 17(5):398-405. PubMed ID: 26936682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nomograms for predicting overall and recurrence-free survival after trimodality therapy for esophageal adenocarcinoma.
    Merritt RE; Abdel-Rasoul M; Souza DM; Kneuertz PJ
    J Surg Oncol; 2021 Mar; 123(4):881-890. PubMed ID: 33333590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy.
    Lan K; Zhu J; Zhang J; Zhou S; Yang Y; Feng Z; Zhang L; Wang S; Xi M
    Radiother Oncol; 2020 Aug; 149():228-235. PubMed ID: 32474127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
    Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP
    Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma].
    Ren XJ; Wang L; Han C; Liu LL
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):135-139. PubMed ID: 30862144
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment and survival outcomes of small cell carcinoma of the esophagus: an analysis of the National Cancer Data Base.
    Wong AT; Shao M; Rineer J; Osborn V; Schwartz D; Schreiber D
    Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27860114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: ResultsĀ from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensity-Modulated Radiation Therapy Is Not Associated with Perioperative or Survival Benefit over 3D-Conformal Radiotherapy for Rectal Cancer.
    Sun Z; Adam MA; Kim J; Czito B; Mantyh C; Migaly J
    J Gastrointest Surg; 2017 Jan; 21(1):106-111. PubMed ID: 27510332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer: predictors of use and outcomes.
    Buckstein M; Rhome R; Ru M; Moshier E
    Dis Esophagus; 2018 May; 31(5):. PubMed ID: 29309563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of pathologic node-positive disease following initial surgery for clinical T1-2 N0 esophageal cancer: patterns of care and outcomes from the national cancer data base.
    Haque W; Verma V; Bernicker E; Butler EB; Teh BS
    Acta Oncol; 2018 Jun; 57(6):782-789. PubMed ID: 29188742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
    Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
    Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
    Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
    J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.